- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05296447
Langtidsopfølgningsundersøgelse af RGX-314 administreret i det suprachoroidale rum for deltagere med diabetisk retinopati
En langsigtet opfølgningsundersøgelse for at evaluere sikkerheden og effektiviteten af suprachoroidal administration af RGX-314 til diabetisk retinopati uden center involveret-diabetisk makulært ødem
This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of DR with and without center involved-diabetic macular edema (CI-DME) in which they received suprachoroidal space (SCS) administration of ABBV-RGX-314. Enrollment of each participant in the current study should occur after the participant has completed either the end of study or early discontinuation visit in the previous (parent) clinical study. Participants will be followed for a total of 5 years post-ABBV-RGX-314 administration (inclusive of the parent study). As such, the total study duration for each participant may vary depending on when they enroll in the current study following ABBV-RGX-314 administration in the parent study.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85014
- Retinal Research Institute, LLC
-
-
California
-
Bakersfield, California, Forenede Stater, 93309
- California Retina Consultants
-
Beverly Hills, California, Forenede Stater, 90211
- Retina-Vitreous Associates Medical Group
-
Los Angeles, California, Forenede Stater, 90017
- Retinal Diagnostic Center
-
Mountain View, California, Forenede Stater, 94040
- Northern California Retina Vitreous Associates Medical Group Inc
-
Pasadena, California, Forenede Stater, 91107
- California Eye Specialists Medical Group, Inc
-
Poway, California, Forenede Stater, 92064
- Retina Consultants San Diego
-
Santa Barbara, California, Forenede Stater, 93103
- California Retina Consultants CRC
-
-
Georgia
-
Augusta, Georgia, Forenede Stater, 30909
- Southeast Retina Center, PC
-
-
Illinois
-
Oak Forest, Illinois, Forenede Stater, 60452
- University Retina and Macula Associates, PC
-
-
Maryland
-
Hagerstown, Maryland, Forenede Stater, 21740
- Cumberland Valley Retina Consultants
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Ophthalmic Consultants of Boston
-
-
Nevada
-
Reno, Nevada, Forenede Stater, 89502
- Sierra eye Associates
-
-
New Jersey
-
Teaneck, New Jersey, Forenede Stater, 07666
- New Jersey Retina
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87109
- Vision Research Center Eye Associates of New Mexico
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27705
- Duke University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19107
- Mid Atlantic Retina
-
-
Tennessee
-
Germantown, Tennessee, Forenede Stater, 38138
- Charles Retina Institute, P.C
-
-
Texas
-
Austin, Texas, Forenede Stater, 78750
- Austin Clinical Research
-
The Woodlands, Texas, Forenede Stater, 77384
- Retina Consultants of Texas
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Must provide written, signed informed consent for this study
- Must have been enrolled in a previous clinical study of ABBV-RGX-314 for the treatment of DR with or without CI-DME and must have received an SCS injection of ABBV-RGX-314 in that study
- Must be willing and able to comply with all study procedures
Exclusion Criteria:
- None
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Andet: Standard of Care
Dose Level (DL) 1-3 participants who received ABBV-RGX-314 in a parent study will continue to receive standard of care for the study duration. |
Standard of Care |
|
Andet: Supplemental Treatment
DL4 participants from parent study will be eligible to receive supplement aflibercept through a prespecified timepoint based on protocol-specified criteria if they develop worsening CI-DME or high-risk proliferative diabetic retinopathy (PDR) in the study eye. |
Standard of Care Injection
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of ocular adverse events (AEs) and any serious adverse events (SAEs)
Tidsramme: 5 years inclusive of the parent study
|
To evaluate the long-term safety of ABBV-RGX-314 |
5 years inclusive of the parent study
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Andel af deltagere, der har behov for yderligere intervention for okulære diabetiske komplikationer (f.eks. anti-VEGF intravitreal injektion eller PRP)
Tidsramme: 5 år, inklusive forældrestudiet
|
5 år, inklusive forældrestudiet
|
|
Andel af deltagere med eventuelle synstruende okulære diabetiske komplikationer
Tidsramme: 5 år, inklusive forældrestudiet
|
5 år, inklusive forældrestudiet
|
|
Incidences of non-ocular AEs and any Adverse Events of Special Interest
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in DR by ETDRS-DRSS on digital stereoscopic fundus photography
Tidsramme: 5 years, inclusive of the parent study
|
5 years, inclusive of the parent study
|
|
Proportion of participants achieving 0-step (no change), a ≥1-step, a ≥2-step, or a ≥3-step or greater change in DR per ETDRS-DRSS on digital stereoscopic fundus photography from baseline (ie, prior to ABBV-RGX-314 administration in the parent study)
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in BCVA
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Proportion of participants gaining or losing ≥ 5, 10, and 15 letters in BCVA compared with baseline (ie, prior to ABBV-RGX-314 administration in the parent study)
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in CST as measured by SD-OCT
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in the area of retinal nonperfusion on ultra-widefield Optos FA
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean number of anti-VEGF injections through years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean number of anti-VEGF injections in years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean anti-VEGF injection annualized rate through years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean anti-VEGF injection annualized rate in years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
|
Mean number of retina specialist visits attended for complications of DR based on chart review
Tidsramme: 5 years, inclusive to the parent study
|
5 years, inclusive to the parent study
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i det endokrine system
- Karsygdomme
- Hjerte-kar-sygdomme
- Diabetes mellitus
- Øjensygdomme
- Diabetiske angiopatier
- Diabetes komplikationer
- Nethindesygdomme
- Diabetisk retinopati
- Sundhedstjenester Administration
- Sundhedsvæsenets kvalitet, adgang og evaluering
- Sundhedskvalitet
- Kvalitetsindikatorer, sundhedsvæsenet
- Standard for pleje
- Aflibercept
Andre undersøgelses-id-numre
- RGX-314-5201 (M23-420)
- M23-420 (Anden identifikator: AbbVie Inc)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD-delingstidsramme
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD-delingsadgangskriterier
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .